--- title: "Weekly Recap | Regeneron Pharma -2.54%, spike fades after 52-week high" type: "News" locale: "en" url: "https://longbridge.com/en/news/304724985.md" description: "Regeneron Pharma fell 2.54% for the week to close at $904.35, edging out the S&P 500 by about 0.14 percentage points. The week followed a spike-and-fade pattern: Monday and Tuesday climbed, with Tuesday ending at $973.36; Wednesday touched a 52-week high of $991.73 before reversing to close at $930.67; Thursday slid further to $902.90; Friday opened at $887.04 and recovered slightly into the close. Weekly amplitude reached 11.29%, and average daily volume of 1.36m shares ran 116." datetime: "2026-11-07T08:45:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/304724985.md) - [en](https://longbridge.com/en/news/304724985.md) - [zh-HK](https://longbridge.com/zh-HK/news/304724985.md) generator: "portal-rs" --- # Weekly Recap | Regeneron Pharma -2.54%, spike fades after 52-week high ## The Week Regeneron Pharma fell 2.54% for the week to close at $904.35, edging out the S&P 500 by about 0.14 percentage points. The week followed a spike-and-fade pattern: Monday and Tuesday climbed, with Tuesday ending at $973.36; Wednesday touched a 52-week high of $991.73 before reversing to close at $930.67; Thursday slid further to $902.90; Friday opened at $887.04 and recovered slightly into the close. Weekly amplitude reached 11.29%, and average daily volume of 1.36m shares ran 116.15% above the 60-day median of 628k. ## Key Events The week’s storyline centred on the aftermath of a strong Q3 report. Early in the week, several brokers revised their views: BMO lifted its target from $920 to $1,050, and Canaccord Genuity from $922 to $1,175. Full Dupixent profit recognition was a recurring theme, with one forecast pointing to $930.46 as the next test. Regeneron hit a 52-week high in premarket trading on Wednesday, but gave back part of the week’s gains over the following two sessions. On the company front, Regeneron declared a quarterly dividend of $0.94 per share and confirmed participation in healthcare conferences hosted by Jefferies, Evercore and Citi. Management pushed back against Silicon Valley’s claim that AI can cure all diseases within a decade, arguing that biological complexity is the real hurdle. Several executives disclosed share sales during the week, including EVP Commercial Marion McCourt selling roughly $984k worth of stock and the SVP Controller selling over $3.8m. No material filings were submitted this week. ## Analyst Ratings As of 4 November, 28 institutions covered Regeneron: 15 rated it buy, 4 rated it overweight, 9 rated it hold, with no underweight or sell ratings. The consensus rating is buy, with a consensus target of $977.93, about 8.14% above the latest price of $904.35. Target prices range from $812 to $1,175, a wide spread. Within the biotechnology industry, Regeneron ranks 10th out of 510, above the industry mean of 8 institutions. ## The Week Ahead No company-specific earnings or R&D milestones are scheduled for next week, but the macro calendar is heavy. Tuesday, 10 November, brings US October CPI and core CPI. The market projects core CPI at 2.8% year-on-year and 0.2% month-on-month, with headline CPI at 3.9% year-on-year and 0.3% month-on-month. Monday, 9 November, has wholesale sales data, and Tuesday also includes the NFIB small business optimism index. As a biotech name with an elevated valuation, Regeneron tends to be sensitive to rate and inflation expectations, so a surprise in either direction could shift risk appetite across the sector. The company’s FY2026 annual results are scheduled for 1 February 2027. ## In Short Regeneron’s price action and news flow created tension this week: analyst ratings are uniformly buy, and the consensus target sits above spot, yet the stock faded after printing a 52-week high and closed lower for the week. The latest session’s fund flow showed large-lot money as a net seller while small and medium lots were net buyers. Valuation stands at roughly 19.3x P/E and 2.78x P/B. What comes next is how the market reprices biotech risk appetite after the CPI prints, and whether the company offers new pipeline or commercial updates at its upcoming conference appearances. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [REGN.US](https://longbridge.com/en/quote/REGN.US.md) ## Related News & Research - [3,572 Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by International Assets Investment Management LLC](https://longbridge.com/en/news/304080339.md) - [Regeneron hits 52-week high after “standout” Q3](https://longbridge.com/en/news/303793362.md) - [Sumitomo Mitsui Trust Group Inc. Sells 4,079 Shares of Regeneron Pharmaceuticals, Inc. $REGN](https://longbridge.com/en/news/303957797.md) - [These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results](https://longbridge.com/en/news/303968582.md) - [Regeneron Pharmaceuticals, Inc. (REGN) Reports Up To 80% Liver-Fat Reduction](https://longbridge.com/en/news/304769834.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**